Wedbush Trims Price Target on Praxis Precision Medicines to $40 From $41 After $200 Million Secondary Offering, Maintains Neutral Rating
Wedbush Trims Price Target on Praxis Precision Medicines to $40 From $41 After $200 Million Secondary Offering, Maintains Neutral Rating
在二次发行2亿美元后,Wedbush将Praxis Precision Medicines的目标股价从41美元下调至40美元,维持中性评级
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册